SomaLogic, Inc. (SLGC): Price and Financial Metrics

SomaLogic, Inc. (SLGC): $2.64

-0.21 (-7.37%)

POWR Rating

Component Grades














  • Value is the dimension where SLGC ranks best; there it ranks ahead of 79.67% of US stocks.
  • The strongest trend for SLGC is in Value, which has been heading up over the past 178 days.
  • SLGC ranks lowest in Stability; there it ranks in the 7th percentile.

SLGC Stock Summary

  • SOMALOGIC INC's stock had its IPO on February 23, 2021, making it an older stock than merely 7.31% of US equities in our set.
  • The ratio of debt to operating expenses for SOMALOGIC INC is higher than it is for about only 0.52% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.15 for SOMALOGIC INC; that's greater than it is for just 11.04% of US stocks.
  • If you're looking for stocks that are quantitatively similar to SOMALOGIC INC, a group of peers worth examining would be MNTV, ONVO, SMAR, COUR, and PCOR.
  • To dig deeper into the stock's financial statements, go to SLGC's page on browse-edgar?action=getcompany&CIK=0001837412.

SLGC Valuation Summary

  • In comparison to the median Technology stock, SLGC's price/sales ratio is 126.09% higher, now standing at 5.2.
  • SLGC's price/sales ratio has moved down 0.4 over the prior 21 months.

Below are key valuation metrics over time for SLGC.

Stock Date P/S P/B P/E EV/EBIT
SLGC 2022-11-25 5.2 0.9 -6.4 -1.8
SLGC 2022-11-23 5.0 0.9 -6.2 -1.6
SLGC 2022-11-22 5.2 0.9 -6.3 -1.7
SLGC 2022-11-21 5.8 1.0 -7.1 -2.6
SLGC 2022-11-18 5.5 0.9 -6.8 -2.2
SLGC 2022-11-17 5.1 0.9 -6.2 -1.6

SLGC Stock Price Chart Interactive Chart >

Price chart for SLGC

SLGC Price/Volume Stats

Current price $2.64 52-week high $13.25
Prev. close $2.85 52-week low $2.63
Day low $2.63 Volume 1,113,200
Day high $2.92 Avg. volume 1,405,970
50-day MA $2.99 Dividend yield N/A
200-day MA $5.22 Market Cap 484.32M

SomaLogic, Inc. (SLGC) Company Bio

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGC Latest Social Stream

Loading social stream, please wait...

View Full SLGC Social Stream

Latest SLGC News From Around the Web

Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.

‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5

Cathie Wood has built her career on holding contrarian views and her Ark Invest firm has been known to go against the grain. As such, 2022’s bear market has done little to change her stance. In fact, recently, Wood has been arguing that the Fed’s aggressive monetary stance in its ongoing efforts to curb soaring inflation is misguided. Highlighting deflationary signals, Wood says that unless it changes tack, the Fed’s actions could result in a repeat of the the Great Depression. “If the Fed does not pivot, the set-up will be more like 1929,” Wood opined.

Marty Shtrubel on TipRanks | November 18, 2022

Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes

BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogic’s SomaSignal® tests aid physicians in the risk stratification for cardiovascular disease of their patients. Researchers from the University of California, San Francisco (UCSF) are investigating if these physicians are more likely to prescribe high-risk patients with drugs to aid in blood glucose control, like SGLT2 inhibitors and GLP-

Yahoo | November 17, 2022

SomaLogic Reports Third Quarter 2022 Financial Results

Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million.Core life science revenue of $20.5 million, representing an increase of 2.9% year-over-year and 45.4% compared to the last quarter.On track to reduce operational expenses by $75 million through 2023. Raising 2022 full year revenue guidance to a range of $93 to $98 million, taking into account the $21.2 million in licensing royalty revenue recognized in the third quarter.Cash, cash equivalents, and short-t

Yahoo | November 14, 2022

SomaLogic Teams with Molecular Genomics to Bring the 7,000-Plex SomaScan® Platform to Asia

SINGAPORE and BOULDER, Colo., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers. “We are honored to be able to partner with SomaLogic to bring the industry leading SomaScan Platform to the region,” said Genomax Technologies and Molecular Genomics Chief Execut

Yahoo | November 8, 2022

SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease

SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of deathBOULDER, Colo., Oct. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced findings from key studies demonstrating the broad and deep role proteomics plays in detecting cardiovascular risk, achieving optimal cardiometabolic health, and assessing the correlation of cardiovascular disease with other diseases that are among t

Yahoo | October 31, 2022

Read More 'SLGC' Stories Here

SLGC Price Returns

1-mo -20.00%
3-mo -28.26%
6-mo -57.96%
1-year -77.76%
3-year N/A
5-year N/A
YTD -77.32%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7169 seconds.